Episode # 76 • 11 Aug 2026
GU Oncology: ASCO Highlights & Impacts on Practice
Is GU oncology entering a new era of early intensification and precision therapy? On this episode of the BackTable Tumor Board Podcast, Dr. Katy Beckermann and Dr. Alan Tan break down the latest GU oncology highlights from ASCO, including key updates in prostate, renal cell, and urothelial carcinoma. They discuss new data supporting HRR/BRCA-focused therapy in HSPC, the importance of early biomarker testing, and ongoing debates about overtreatment and real-world practice impact.
Timestamps
00:00 - Introduction
01:56 - Frontline Prostate Cancer & TALAPRO-3 Highlights
07:11 - PROTEUS Plenary Breakdown & Controversies
13:47 - RCC Rampart and ctDNA
19:47 - Bladder EV Pembro Updates
23:34 - Next-Gen Nectin-4 ADC
26:51 - Wrap-Up
Resources
You may also like
More about this episode
The conversation covers the PROTEUS trial and perioperative intensification, RAMPART and Keynote-564 ctDNA findings in RCC, and new standards in perioperative bladder cancer treatment with EV plus pembrolizumab. Drs. Tan and Beckermann also discuss next-generation ADCs, pharmacogenomic toxicity considerations, and the promise of AI and ctDNA for patient selection and de-escalation strategies in advanced GU cancers.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.